Literature DB >> 25787189

Subclinical MRI disease activity influences cognitive performance in MS patients.

Alfredo Damasceno1, Benito Pereira Damasceno2, Fernando Cendes2.   

Abstract

BACKGROUND: The pathological mechanisms underlying cognitive dysfunction in multiple sclerosis (MS) are not yet fully understood and, in addition to demyelinating lesions and gray-matter atrophy, subclinical disease activity may play a role.
OBJECTIVE: To evaluate the contribution of asymptomatic gadolinium-enhancing lesions to cognitive dysfunction along with gray-matter damage and callosal atrophy in relapsing-remitting MS (RRMS) patients.
METHODS: Forty-two treated RRMS and 30 controls were evaluated. MRI (3T) variables of interest were brain white-matter and cortical lesion load, cortical and deep gray-matter volumes, corpus callosum volume and presence of gadolinium-enhancing lesions. Outcome variables included EDSS, MS Functional Composite (MSFC) subtests and the Brief Repeatable Battery of Neuropsychological tests. Cognitive dysfunction was classified as deficits in two or more cognitive subtests. Multivariate regression analyses assessed the contribution of MRI metrics to outcomes.
RESULTS: Patients with cognitive impairment (45.2%) had more cortical lesions and lower gray-matter and callosal volumes. Patients with subclinical MRI activity (15%) had worse cognitive performance. Clinical disability on MSFC was mainly associated with putaminal atrophy. The main independent predictors for cognitive deficits were high burden of cortical lesions and number of gadolinium-enhancing lesions.
CONCLUSIONS: Cognitive dysfunction was especially related to high burden of cortical lesions and subclinical disease activity. Cognitive studies in MS should look over subclinical disease activity as a potential contributor to cognitive impairment.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognition; Corpus callosum; Cortical lesions; MRI; Multiple sclerosis; Subclinical disease activity

Mesh:

Substances:

Year:  2015        PMID: 25787189     DOI: 10.1016/j.msard.2015.01.006

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  5 in total

1.  Multiple sclerosis: neuroimaging provides insights into cognitive dysfunction in MS.

Authors:  Hemi Malkki
Journal:  Nat Rev Neurol       Date:  2015-02-10       Impact factor: 42.937

2.  Perfusion reduction in the absence of structural differences in cognitively impaired versus unimpaired RRMS patients.

Authors:  Seyed-Parsa Hojjat; Charles Grady Cantrell; Timothy J Carroll; Rita Vitorino; Anthony Feinstein; Lying Zhang; Sean P Symons; Sarah A Morrow; Liesly Lee; Paul O'Connor; Richard I Aviv
Journal:  Mult Scler       Date:  2016-02-04       Impact factor: 6.312

3.  Navigator-Guided Motion and B0 Correction of T2*-Weighted Magnetic Resonance Imaging Improves Multiple Sclerosis Cortical Lesion Detection.

Authors:  Jiaen Liu; Erin S Beck; Stefano Filippini; Peter van Gelderen; Jacco A de Zwart; Gina Norato; Pascal Sati; Omar Al-Louzi; Hadar Kolb; Maxime Donadieu; Mark Morrison; Jeff H Duyn; Daniel S Reich
Journal:  Invest Radiol       Date:  2021-07-01       Impact factor: 10.065

4.  Correlation between cortical lesions and cognitive impairment in multiple sclerosis.

Authors:  Erica Curti; Stefania Graziuso; Elena Tsantes; Girolamo Crisi; Franco Granella
Journal:  Brain Behav       Date:  2018-04-21       Impact factor: 2.708

5.  Functional and self-care capacity of people with multiple sclerosis.

Authors:  Ana Railka de Souza Oliveira-Kumakura; Larissa Maria Bezutti; Juliany Lino Gomes Silva; Renata Cristina Gasparino
Journal:  Rev Lat Am Enfermagem       Date:  2019-10-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.